Gene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis

Molecular Therapy

Volumn 26, Issue 1, 2018, Pages 173-183

  Keeler, Geoffrey D ^a   Kumar, Sandeep ^a   Palaschak, Brett ^a   Silverberg, Emily L ^a   Markusic, David M ^a   Jones, Noah T ^a   Hoffman, Brad E ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

adeno associated virus; autoimmunity; experimental autoimmune encephalomyelitis; gene therapy; immunotherapy; regulatory T cell; tolerance; viral vector

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; BIOLOGICAL MARKER; EPITOPE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MOUSE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARALYSIS; REGULATORY T LYMPHOCYTE; SPLEEN; SPLEEN CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WESTERN BLOTTING; ANIMAL; AUTOIMMUNITY; DEPENDOPARVOVIRUS; DISEASE MODEL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENE THERAPY; GENE VECTOR; GENETICS; IMMUNOLOGY; LIVER; METABOLISM; PATHOLOGY; PROCEDURES; SPINAL CORD;

ANIMALS; AUTOIMMUNITY; BIOMARKERS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPITOPES, T-LYMPHOCYTE; GENETIC THERAPY; GENETIC VECTORS; HEPATOCYTES; IMMUNE TOLERANCE; LIVER; MICE; MULTIPLE SCLEROSIS; SPINAL CORD; T-LYMPHOCYTES, REGULATORY;

EID: 85029713288     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2017.09.001     Document Type: Article

References (56)

1. Gonsette, R.E., Self-tolerance in multiple sclerosis. Acta Neurol. Belg. 112 (2012), 133–140.
2. Viglietta, V., Baecher-Allan, C., Weiner, H.L., Hafler, D.A., Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199 (2004), 971–979.
3. Zozulya, A.L., Wiendl, H., The role of regulatory T cells in multiple sclerosis. Nat. Clin. Pract. Neurol. 4 (2008), 384–398.
4. Paust, S., Cantor, H., Regulatory T cells and autoimmune disease. Immunol. Rev. 204 (2005), 195–207.
5. Dalla Libera, D., Di Mitri, D., Bergami, A., Centonze, D., Gasperini, C., Grasso, M.G., Galgani, S., Martinelli, V., Comi, G., Avolio, C., et al. T regulatory cells are markers of disease activity in multiple sclerosis patients. PLoS ONE, 6, 2011, e21386.
6. Carbone, F., De Rosa, V., Carrieri, P.B., Montella, S., Bruzzese, D., Porcellini, A., Procaccini, C., La Cava, A., Matarese, G., Regulatory T cell proliferative potential is impaired in human autoimmune disease. Nat. Med. 20 (2014), 69–74.
7. Vila, J., Isaacs, J.D., Anderson, A.E., Regulatory T cells and autoimmunity. Curr. Opin. Hematol. 16 (2009), 274–279.
8. MacDonald, K.G., Hoeppli, R.E., Huang, Q., Gillies, J., Luciani, D.S., Orban, P.C., Broady, R., Levings, M.K., Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J. Clin. Invest. 126 (2016), 1413–1424.
9. Rossetti, M., Spreafico, R., Saidin, S., Chua, C., Moshref, M., Leong, J.Y., Tan, Y.K., Thumboo, J., van Loosdregt, J., Albani, S., Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region. J. Immunol. 194 (2015), 113–124.
10. Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K.V., Lin, C.H., Hanke, T., Hünig, T., Kerkau, T., Gold, R., Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J. Exp. Med. 202 (2005), 445–455.
11. Thomas, H.R., Gitelman, S.E., Altering the course of type 1 diabetes: an update on prevention and new-onset clinical trials. Pediatr. Diabetes 14 (2013), 311–321.
12. Trzonkowski, P., Bieniaszewska, M., Juścińska, J., Dobyszuk, A., Krzystyniak, A., Marek, N., Myśliwska, J., Hellmann, A., First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin. Immunol. 133 (2009), 22–26.
13. Safinia, N., Sagoo, P., Lechler, R., Lombardi, G., Adoptive regulatory T cell therapy: challenges in clinical transplantation. Curr. Opin. Organ Transplant. 15 (2010), 427–434.
14. Lüth, S., Huber, S., Schramm, C., Buch, T., Zander, S., Stadelmann, C., Brück, W., Wraith, D.C., Herkel, J., Lohse, A.W., Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs. J. Clin. Invest. 118 (2008), 3403–3410.
15. Akbarpour, M., Goudy, K.S., Cantore, A., Russo, F., Sanvito, F., Naldini, L., Annoni, A., Roncarolo, M.G., Insulin B chain 9-23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3+ Tregs. Sci. Transl. Med., 7, 2015, 289ra81.
16. LoDuca, P.A., Hoffman, B.E., Herzog, R.W., Hepatic gene transfer as a means of tolerance induction to transgene products. Curr. Gene Ther. 9 (2009), 104–114.
17. Sack, B.K., Herzog, R.W., Terhorst, C., Markusic, D.M., Development of gene transfer for induction of antigen-specific tolerance. Mol. Ther. Methods Clin. Dev., 1, 2014, 14013.
18. Kerlero de Rosbo, N., Milo, R., Lees, M.B., Burger, D., Bernard, C.C., Ben-Nun, A., Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J. Clin. Invest. 92 (1993), 2602–2608.
19. Varrin-Doyer, M., Shetty, A., Spencer, C.M., Schulze-Topphoff, U., Weber, M.S., Bernard, C.C., Forsthuber, T., Cree, B.A., Slavin, A.J., Zamvil, S.S., MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS. Neurol. Neuroimmunol. Neuroinflamm., 1, 2014, e20.
20. Hoffman, B., Dobrzynski, E., Wang, L., Hirao, L., Mingozzi, F., Cao, O., Herzog, R.W., Muscle as a target for supplementary factor IX gene transfer. Hum. Gene Ther. 18 (2007), 603–613.
21. Korn, T., Reddy, J., Gao, W., Bettelli, E., Awasthi, A., Petersen, T.R., Bäckström, B.T., Sobel, R.A., Wucherpfennig, K.W., Strom, T.B., et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 13 (2007), 423–431.
22. Cao, O., Dobrzynski, E., Wang, L., Nayak, S., Mingle, B., Terhorst, C., Herzog, R.W., Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 110 (2007), 1132–1140.
23. Mingozzi, F., High, K.A., Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122 (2013), 23–36.
24. Kim, W.R., Flamm, S.L., Di Bisceglie, A.M., Bodenheimer, H.C., Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 47 (2008), 1363–1370.
25. Pedotti, R., Mitchell, D., Wedemeyer, J., Karpuj, M., Chabas, D., Hattab, E.M., Tsai, M., Galli, S.J., Steinman, L., An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat. Immunol. 2 (2001), 216–222.
26. Zhang, L., Guo, Y., Xia, C.Q., Infusion of sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate-conjugated MOG35-55-coupled spleen cells effectively prevents and reverses experimental autoimmune encephalomyelitis in mice. J. Immunol. Res., 2015, 2015, 129682.
27. Tse, H.Y., Li, J., Zhao, X., Chen, F., Ho, P.P., Shaw, M.K., Lessons learned from studies of natural resistance in murine experimental autoimmune encephalomyelitis. Curr. Trends Immunol. 13 (2012), 1–12.
28. Raine, C.S., Traugott, U., Stone, S.H., Applications of chronic relapsing experimental allergic encephalomyelitis to the study of multiple sclerosis. Bauer, H.J., Poser, S., Ritter, G., (eds.) Progress in Multiple Sclerosis Research, 1980, Springer Berlin Heidelberg, 3–10.
29. Markusic, D.M., Hoffman, B.E., Perrin, G.Q., Nayak, S., Wang, X., LoDuca, P.A., High, K.A., Herzog, R.W., Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO Mol. Med. 5 (2013), 1698–1709.
30. Marcus, J.F., Waubant, E.L., Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis. Neurohospitalist 3 (2013), 65–80.
31. Kohm, A.P., Carpentier, P.A., Anger, H.A., Miller, S.D., Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169 (2002), 4712–4716.
32. Berard, J.L., Wolak, K., Fournier, S., David, S., Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice. Glia 58 (2010), 434–445.
33. Bluestone, J.A., Bour-Jordan, H., Cheng, M., Anderson, M., T cells in the control of organ-specific autoimmunity. J. Clin. Invest. 125 (2015), 2250–2260.
34. Nie, H., Zheng, Y., Li, R., Guo, T.B., He, D., Fang, L., Liu, X., Xiao, L., Chen, X., Wan, B., et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis. Nat. Med. 19 (2013), 322–328.
35. Esposito, M., Ruffini, F., Bellone, M., Gagliani, N., Battaglia, M., Martino, G., Furlan, R., Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. J. Neuroimmunol. 220 (2010), 52–63.
36. Biswas, M., Sarkar, D., Kumar, S.R., Nayak, S., Rogers, G.L., Markusic, D.M., Liao, G., Terhorst, C., Herzog, R.W., Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg. Blood 125 (2015), 2937–2947.
37. Battaglia, M., Stabilini, A., Roncarolo, M.G., Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105 (2005), 4743–4748.
38. Liu, T., Soong, L., Liu, G., König, R., Chopra, A.K., CD44 expression positively correlates with Foxp3 expression and suppressive function of CD4+ Treg cells. Biol. Direct, 4, 2009, 40.
39. Li, M.O., Rudensky, A.Y., T cell receptor signalling in the control of regulatory T cell differentiation and function. Nat. Rev. Immunol. 16 (2016), 220–233.
40. Lallana, E.C., Fadul, C.E., Toxicities of immunosuppressive treatment of autoimmune neurologic diseases. Curr. Neuropharmacol. 9 (2011), 468–477.
41. Gregori, S., Passerini, L., Roncarolo, M.G., Clinical outlook for type-1 and FOXP3(+) T regulatory cell-based therapy. Front. Immunol., 6, 2015, 593.
42. Brunstein, C.G., Blazar, B.R., Miller, J.S., Cao, Q., Hippen, K.L., McKenna, D.H., Curtsinger, J., McGlave, P.B., Wagner, J.E., Adoptive transfer of umbilical cord blood-derived regulatory T cells and early viral reactivation. Biol. Blood Marrow Transplant. 19 (2013), 1271–1273.
43. Josefowicz, S.Z., Lu, L.F., Rudensky, A.Y., Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30 (2012), 531–564.
44. McGeachy, M.J., Stephens, L.A., Anderton, S.M., Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J. Immunol. 175 (2005), 3025–3032.
45. Desreumaux, P., Foussat, A., Allez, M., Beaugerie, L., Hébuterne, X., Bouhnik, Y., Nachury, M., Brun, V., Bastian, H., Belmonte, N., et al. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology 143 (2012), 1207–1217 e1–e2.
46. Hoffman, B.E., Martino, A.T., Sack, B.K., Cao, O., Liao, G., Terhorst, C., Herzog, R.W., Nonredundant roles of IL-10 and TGF-β in suppression of immune responses to hepatic AAV-factor IX gene transfer. Mol. Ther. 19 (2011), 1263–1272.
47. Chen, X., Oppenheim, J.J., Winkler-Pickett, R.T., Ortaldo, J.R., Howard, O.M., Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur. J. Immunol. 36 (2006), 2139–2149.
48. O'Connor, R.A., Anderton, S.M., Foxp3+ regulatory T cells in the control of experimental CNS autoimmune disease. J. Neuroimmunol. 193 (2008), 1–11.
49. Hoffman, B.E., Ertl, H.C., Terhorst, C., High, K.A., Herzog, R.W., Gene therapy research at the frontiers of viral immunology. Front. Microbiol., 3, 2012, 182.
50. Cao, O., Hoffman, B.E., Moghimi, B., Nayak, S., Cooper, M., Zhou, S., Ertl, H.C., High, K.A., Herzog, R.W., Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol. Ther. 17 (2009), 1733–1742.
51. Cooper, M., Nayak, S., Hoffman, B.E., Terhorst, C., Cao, O., Herzog, R.W., Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Hum. Gene Ther. 20 (2009), 767–776.
52. Chapman, N.M., Chi, H., mTOR signaling, Tregs and immune modulation. Immunotherapy 6 (2014), 1295–1311.
53. Battaglia, M., Stabilini, A., Migliavacca, B., Horejs-Hoeck, J., Kaupper, T., Roncarolo, M.G., Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 177 (2006), 8338–8347.
54. Moghimi, B., Sack, B.K., Nayak, S., Markusic, D.M., Mah, C.S., Herzog, R.W., Induction of tolerance to factor VIII by transient co-administration with rapamycin. J. Thromb. Haemost. 9 (2011), 1524–1533.
55. Zolotukhin, S., Potter, M., Zolotukhin, I., Sakai, Y., Loiler, S., Fraites, T.J. Jr., Chiodo, V.A., Phillipsberg, T., Muzyczka, N., Hauswirth, W.W., et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28 (2002), 158–167.
56. Martino, A.T., Suzuki, M., Markusic, D.M., Zolotukhin, I., Ryals, R.C., Moghimi, B., Ertl, H.C., Muruve, D.A., Lee, B., Herzog, R.W., The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 117 (2011), 6459–6468.